Evidence map›Paper›PMID 42620698›Full record

ArticleFrontiers in oncology2026

Case Report: a hypermetabolic mediastinal mass (SUVmax 16.7) mimicking malignancy with spontaneous resolution: an inflammatory myofibroblastic proliferation and diagnostic pitfall.

Zhe Li, Zhuo Zhang, Baolei Lyu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhe LiDepartment of Thoracic Surgery, Shijiazhuang People's Hospital, Shijiazhuang, China.
Zhuo ZhangDepartment of Pathology, Shijiazhuang People's Hospital, Shijiazhuang, China.
Baolei LyuDepartment of Thoracic Surgery, Shijiazhuang People's Hospital, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hypermetabolic mediastinal masses on 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) are presumed malignant until proven otherwise. However, benign inflammatory and organizing processes may exhibit equally intense metabolic activity, posing a diagnostic challenge-particularly when the lesion abuts major vascular structures and limits safe tissue sampling. Case summary: A 55-year-old male smoker presented with cough, right-sided chest pain, low-grade fever, and mild dysphagia. Contrast-enhanced CT identified an ill-defined mass in the retrotracheal region of the superior mediastinum (within the tracheoesophageal groove), measuring 1.8×2.6×3.2 cm, with poorly defined margins against the esophagus and heterogeneous enhancement (precontrast attenuation 17-41 Hounsfield units (HU)). [18F]FDG PET/CT demonstrated markedly elevated [18F]FDG uptake (maximum standardized uptake value [SUVmax], 16.7), raising strong suspicion for malignancy. Serum tumor markers, procalcitonin, interleukin-6, and total immunoglobulin E (IgE) were within normal limits; sputum acid-fast, fungal, and bacterial cultures were negative, as were Epstein-Barr virus, cytomegalovirus, and a respiratory virus panel. Endobronchial ultrasound (EBUS)-guided aspiration did not yield a diagnostic specimen. CT-guided core needle biopsy was safely performed despite proximity to the superior vena cava and aortic arch, without complications. Histopathology revealed fibrocollagenous tissue with lymphoplasmacytic infiltration and foamy histiocytes, without malignant cells. Immunohistochemistry showed anaplastic lymphoma kinase (ALK) negativity, smooth muscle actin (SMA) positivity, and immunoglobulin G4 (IgG4) sparse focal weak positivity (below the threshold for IgG4-related disease), and a Ki-67 index of approximately 30% that labeled predominantly inflammatory cells rather than spindle cells, consistent with an inflammatory myofibroblastic proliferation. No antineoplastic, further targeted antimicrobial, or immunosuppressive therapy was administered. Follow-up CT at approximately 2.5 months demonstrated complete spontaneous resolution of the mass. A repeat chest CT in July 2026, approximately 2 months after the scan that first documented complete resolution, continued to show no residual or recurrent mediastinal lesion. Taken together, the findings favored an inflammatory myofibroblastic proliferation with an organizing, self-limiting course, while acknowledging that complete distinction from an ALK-negative inflammatory myofibroblastic tumor cannot be made with absolute certainty on limited core-biopsy material alone. Conclusion: An inflammatory myofibroblastic proliferation in the mediastinum may exhibit extreme FDG avidity (SUVmax 16.7) indistinguishable from malignancy on imaging. A Ki-67 index of ~30% that labels predominantly inflammatory cells supports reactive proliferative activity as a histological correlate of the elevated metabolic signal, whereas complete spontaneous resolution sustained on repeat CT supports a self-limiting inflammatory course. When tissue sampling and subsequent clinical evolution make malignancy and active infection less likely, short-interval imaging surveillance may be an appropriate strategy in carefully selected patients.

Indexed as

18F-FDG PET/CTCT-guided core biopsydiagnostic pitfallinflammatory myofibroblastic proliferationKi-67mediastinal massretrotrachealspontaneous resolution

Identifiers

PMID42620698
PMCPMC13485795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.